Physician profile
Eileen Hunt
NPI 1528767464
$1,343.33
in general payments reported to CMS, 2019-2025
16 companies · $629 in 2025
The $629 reported for 2025 was more than what 77% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $172 · 2024: $543 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.79 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $243.05 | 2024-2025 | Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $196.80 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $150.43 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $107.99 | 2023-2024 | Repatha, Otezla |
| Daiichi Sankyo INC. | $80.03 | 2024 | Injectafer |
| Lilly USA, LLC | $53.62 | 2023-2025 | Zepbound, Mounjaro, Emgality |
| Abbott Laboratories | $43.64 | 2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $29.15 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $27.70 | 2025 | |
| Merck Sharp & Dohme LLC | $23.73 | 2025 | Capvaxive, Gardasil 9 |
| Corcept Therapeutics | $22.62 | 2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $21.95 | 2025 | Recorlev |
| Kowa Pharmaceuticals America, INC. | $16.57 | 2023 | Livalo |
| Abbvie INC. | $16.48 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13.78 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.